Echocardiographic phenotype for refined risk stratification and treatment selection in light chain amyloidosis with heart failure

被引:1
作者
Yang, Hong [1 ,2 ]
Li, Rui [1 ,2 ]
Ma, Fei [1 ,2 ]
Liu, Yujian [1 ,2 ]
He, Xingwei [1 ,2 ]
Yang, Qiao [1 ,2 ]
Wang, Dao Wen [1 ,2 ]
Zeng, Hesong [1 ,2 ]
Wang, Hong [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Div Cardiol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
关键词
Light chain amyloidosis; Cardiac amyloidosis; Heart failure; Mayo staging system; Echocardiography; SPECKLE-TRACKING ECHOCARDIOGRAPHY; PRIMARY SYSTEMIC AMYLOIDOSIS; CORONARY-ARTERY-DISEASE; LONGITUDINAL STRAIN; NATRIURETIC PEPTIDE; CARDIAC AMYLOIDOSIS; AMERICAN-SOCIETY; STAGING SYSTEM; TASK-FORCE; AL;
D O I
10.1007/s00432-023-04783-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AimsLight chain amyloidosis (AL) patients with heart failure (HF) are usually with revised Mayo (rMayo) stage III/IV disease and have a poor prognosis. We sought to investigate whether and what echocardiographic phenotype provides value for further risk stratification and guiding optimal risk-adapted treatment in this subgroup of AL patients.Methods and Results95 AL patients who presented with HF and were on rMayo stage III/IV were retrospectively included. Of them, 51 patients (53.7%) were with stage III, 44 (46.3%) were with stage IV, and 44 (46.3%) underwent chemotherapy. Laboratory and echocardiographic measurements were acquired before the initiation of chemotherapy. The relevance of different variables with survival was assessed in the entire cohort, chemotherapy, and non-chemotherapy group. By Multivariate Cox regression analysis, right ventricular wall thickness (RVT) [HR 1.145, 95% confidence interval (CI) 1.026-1.279, P = 0.016], relative wall thickness (RWT) (HR 6.709, 95% CI 1.101-40.877, P = 0.039), and left ventricular ejection fraction (LVEF) < 50% (HR 1.939, 95% CI 1.048-3.590, P = 0.035) were found to be independently associated with survival in the entire cohort, RWT (HR 15.488, 95% CI 2.045-117.292, P = 0.008) in the non-chemotherapy group, and RVT (HR 1.331, 95% CI 1.054-1.681, P = 0.016) in the chemotherapy group, respectively. Kaplan-Meier survival analysis revealed that survival was significantly reduced in the presence of RVT >= 6.5 mm or LVEF < 50% in the entire cohort, and the significance of RVT >= 6.5 mm was irrespective of rMayo stages. In the chemotherapy group, survival was decreased if RVT >= 6.5 mm alone or together with RWT >= 0.67 were present, particularly in patients on rMayo stage IV.ConclusionsEchocardiographic phenotype provides incremental value beyond rMayo staging for predicting survival and could further guide treatment in advanced AL with HF. Those with high-risk echocardiographic phenotypes as higher RVT and RWT and lower LVEF had a worse prognosis.
引用
收藏
页码:8415 / 8427
页数:13
相关论文
共 45 条
  • [31] Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
    Nagueh, Sherif F.
    Smiseth, Otto A.
    Appleton, Christopher P.
    Byrd, Benjamin F., III
    Dokainish, Hisham
    Edvardsen, Thor
    Flachskampf, Frank A.
    Gillebert, Thierry C.
    Klein, Allan L.
    Lancellotti, Patrizio
    Marino, Paolo
    Oh, Jae K.
    Popescu, Bogdan Alexandru
    Waggoner, Alan D.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2016, 29 (04) : 277 - 314
  • [32] Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure?
    Nordlinger, M
    Magnani, B
    Skinner, M
    Falk, RH
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (07) : 982 - 984
  • [33] Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters
    Pagourelias, Efstathios D.
    Mirea, Oana
    Duchenne, Juergen
    Van Cleemput, Johan
    Delforge, Michel
    Bogaert, Jan
    Kuznetsova, Tatyana
    Voigt, Jens-Uwe
    [J]. CIRCULATION-CARDIOVASCULAR IMAGING, 2017, 10 (03)
  • [34] The relationship of plasma creatinine (as eGFR) and high-sensitivity cardiac troponin and NT-proBNP concentrations in a hospital and community outpatient population
    Potter, Julia M.
    Simpson, Aaron J.
    Kerrigan, Jennifer
    Southcott, Emma
    Salib, Marie M.
    Koerbin, Gus
    Hickman, Peter E.
    [J]. CLINICAL BIOCHEMISTRY, 2017, 50 (15) : 813 - 815
  • [35] Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation
    Pun, Shawn C.
    Landau, Heather J.
    Riedel, Elyn R.
    Jordan, Jonathan
    Yu, Anthony F.
    Hassoun, Hani
    Chen, Carol L.
    Steingart, Richard M.
    Liu, Jennifer E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2018, 31 (01) : 64 - 70
  • [36] Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis
    Salinaro, Francesco
    Meier-Ewert, Hans K.
    Miller, Edward J.
    Pandey, Shivda
    Sanchorawalats, Vaishali
    Berk, John L.
    Seldints, David C.
    Ruberg, Frederick L.
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2017, 18 (09) : 1057 - 1064
  • [37] Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines
    Sanchorawala, Vaishali
    Boccadoro, Mario
    Gertz, Morie
    Hegenbart, Ute
    Kastritis, Efstathios
    Landau, Heather
    Mollee, Peter
    Wechalekar, Ashutosh
    Palladini, Giovanni
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2022, 29 (01): : 1 - 7
  • [38] A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
    Sanchorawala, Vaishali
    Palladini, Giovanni
    Kukreti, Vishal
    Zonder, Jeffrey A.
    Cohen, Adam D.
    Seldin, David C.
    Dispenzieri, Angela
    Jaccard, Arnaud
    Schoenland, Stefan O.
    Berg, Deborah
    Yang, Huyuan
    Gupta, Neeraj
    Hui, Ai-Min
    Comenzo, Raymond L.
    Merlini, Giampaolo
    [J]. BLOOD, 2017, 130 (05) : 597 - 605
  • [39] Chemotherapy to Treat Heart Failure
    Semigran, Marc J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (25) : 2949 - 2951
  • [40] Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure
    Sperry, Brett W.
    Ikram, Asad
    Hachamovitch, Rory
    Valent, Jason
    Vranian, Michael N.
    Phelan, Dermot
    Hanna, Mazen
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (25) : 2941 - 2948